BIRC5 and breast carcinoma: Moderate to high serum levels of Survivin were detected in 86% of triple negative (ER-PR-Her2-) breast cancer, and 83% of patients with ER and PR positive, Her2 negative (ER + PR + Her2-) receptor status (Table 2).